Veru Inc ((VERU)) has held its Q1 earnings call. Read on for the main highlights of the call.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Veru Inc’s latest earnings call painted a mixed picture of the company’s recent performance and strategic direction. While there were notable achievements in the clinical advancement of enobosarm and some financial gains from debt extinguishment, concerns were raised about financial challenges, including increased R&D costs and negative cash flow.
Successful Phase 2b QUALITY Clinical Study
The Phase 2b QUALITY clinical study was a highlight for Veru Inc, demonstrating positive top-line results for the drug enobosarm. The study achieved its primary endpoint with a significant 71% relative reduction in lean mass loss, and the 3-milligram dose showed even more impressive results with a 99% mean relative reduction in lean mass loss. These results underscore the potential of enobosarm as a therapeutic agent.
Enobosarm’s Impact on Fat Loss
In addition to its effects on muscle preservation, enobosarm also showed promising results in fat loss. The treatment led to a 46% greater relative loss of fat mass compared to the placebo group at 16 weeks, with the 3-milligram dose achieving a remarkable 99.1% fat loss. These findings indicate enobosarm’s dual benefit in both muscle and fat management.
Improvement in Physical Function
Veru Inc reported improvements in physical function with the enobosarm plus semaglutide treatment. The combination resulted in a 54.4% mean relative reduction in the proportion of subjects experiencing a significant loss in stair climb power, showcasing potential benefits for physical mobility in patients.
Strategic Focus on Biopharmaceutical Development
In a strategic move, Veru sold its FC2 female condom business for $18 million. This sale reflects the company’s pivot towards focusing on drug development, particularly in the biopharmaceutical sector, allowing it to concentrate resources and efforts on advancing its clinical pipeline.
Financial Gains from Debt Extinguishment
Veru Inc recorded a financial gain of $8.6 million through the extinguishment of debt related to the termination of a residual royalty agreement. This gain highlights the company’s efforts to strengthen its financial standing amidst various operational challenges.
Loss on Sale of FC2 Business
Despite the strategic sale of the FC2 business, Veru reported a $4.2 million loss, with net proceeds of $16.4 million against a carrying value of $20.6 million. This loss underscores some of the financial trade-offs involved in the company’s strategic realignment.
Increased Research and Development Costs
Veru’s commitment to advancing its clinical trials is reflected in the significant increase in research and development costs, which rose to $5.7 million from $1.7 million in the previous quarter. These costs are primarily associated with the ongoing enobosarm Phase 2b QUALITY clinical study.
Negative Cash Flow from Operations
The company reported a negative cash flow from operations, having used $11.3 million for operating activities in the last quarter compared to $6 million previously. This highlights the financial strain the company faces as it invests in its clinical development programs.
Limited Cash Runway
Veru Inc’s financial outlook indicates that its current cash reserves are insufficient to sustain operations for the next 15 months, although they can support activities until the end of the calendar year. This raises concerns about the company’s long-term financial viability.
Forward-Looking Guidance
Looking ahead, Veru Inc provided guidance based on its recent clinical success and strategic decisions. The company plans to pursue a Phase III study for enobosarm, building on its promising Phase 2b results, and is exploring the development of sabizabulin for treating inflammation in atherosclerotic cardiovascular disease. Financially, Veru reported a net loss of $1.8 million from continuing operations, with a total cash balance of $26.6 million. The strategic shift following the sale of the FC2 business is expected to support its biopharmaceutical focus.
In summary, Veru Inc’s earnings call offered a blend of optimism and caution. While the clinical progress of enobosarm is promising, financial challenges persist. The company’s strategic shift towards biopharmaceutical development, supported by recent financial maneuvers, reflects a calculated effort to navigate these challenges while pursuing future growth.
